NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.

@article{Wierda2017NCCNGI,
  title={NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.},
  author={William G Wierda and John C. Byrd and Jeremy S Abramson and Syed Fazil Bilgrami and Greg R Bociek and Danielle M Brander and Jennifer Bruning Brown and Asher Alban Chanan-Khan and Julio C Ch{\'a}vez and Steve E Coutre and Randall S Davis and Christopher D. M. Fletcher and Brian Hill and Brad S Kahl and Manali K. Kamdar and Lawrence D. Kaplan and Nadia Khan and Thomas J. Kipps and Shuo Ma and Sami A. Malek and Anthony R. Mato and Claudio A. Mosse and Vishala T. Neppalli and Mazyar Shadman and Tanya Siddiqi and Deborah Ann Stephens and Nina K{\"u}nzler Wagner and Mary A. Dwyer and Hema M. Sundar},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  year={2017},
  volume={17 1},
  pages={
          12-20
        }
}
Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter's transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation. 
BETA
11
Twitter Mentions